A Landscape of Artificial Intelligence (AI) In Pharmaceutical R&D

Where you find opportunities to grow

* Can't find your brand, product, service? Join BPT Marketplace

Cell Therapies


Cytovia Therapeutics and NYSCF Annouce Filing of Provisional Patent for iPSC-derived NK Cells to Produce Unlimited On-demand NK and CAR-NK Cells for the Treatment of Cancer

   by Charlotte Tomic    160
Cytovia Therapeutics and NYSCF Annouce Filing of Provisional Patent for iPSC-derived NK Cells to Produce Unlimited On-demand NK and CAR-NK Cells for the Treatment of Cancer

(August 25, 2020)--New York, NY--Cytovia Therapeutics, an emerging biopharmaceutical company and the New York Stem Cell Foundation (NYSCF) Research Institute today announced the filing of a provisional patent application with the U.S. Patent & Trademark Office (USPTO) for the differentiation of Natural Killer (NK) cells from induced pluripotent stem cells (iPSCs). The NYSCF Research Institute is a pioneer and acknowledged leader in stem cell technology, having developed the NYSCF Global Stem Cell Array®, the premier automated robotic platform for reprogramming skin or blood into induced pluripotent stem cells (iPSCs) and differentiating them into disease-relevant cell types.

 

[Interview] Advancing Off-the-shelf Cellular Medicines to Fight COVID-19

   by Andrii Buvailo    1752
[Interview] Advancing Off-the-shelf Cellular Medicines to Fight COVID-19

Mesoblast Limited (Nasdaq:MESO; ASX:MSB), a world leader in developing allogeneic (off-the-shelf) cellular medicines, just announced that the first COVID-19 infected patients have been dosed with remestemcel-L, the company’s proprietary allogeneic cellular medicine. This study is conducted within the framework of the 300-patient randomized placebo-controlled Phase 3 trial underway in North America which focuses on patients with moderate to severe acute respiratory distress syndrome (ARDS) on ventilator support.